TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05596747
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC.
Study: NCT00000454
Drug: nicotine replacement patch
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06478134
Drug: Hyaluronic acid tear substitute
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were instructed to instill 1 drop of 0.15% HA tear substitute into each eye 3 times per day for 6 months.
Study: NCT04614298
Drug: KHK4827-Active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SC administration
Study: NCT05923502
Drug: Duvelisib
Normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.
Study: NCT05054465
Drug: Navitoclax
Normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P.O 50mg QD Q28 days for 2 cycles pre-transplant Up to 50mg QD Q28 days maintnance post-transplant based on MTD
Study: NCT05054465
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: P.O 400mg QD Q28 days for 2 cycles pre-transplant Up to 400mg QD Q28 days maintnance post-transplant based on MTD
Study: NCT04940013
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants are given misoprostol alone for menstrual regulation.
Study: NCT00237861
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00237861
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00237861
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05041725
Drug: Remimazolam Injection [Byfavo]
Normalized name: remimazolam Injection [Byfavo]
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam injection and continuous infusion for postoperative sedation, 0.2 mg/kg for 1 min and continuous infusion of 1-2 mg/kg/hour
Study: NCT04366518
Drug: Rivastigmine Transdermal System
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine doses will be administered transdermally using 9.5 mg/24 hr transdermal patches. Participants will be randomized to two treatments with oral rivastigmine vs. placebo separated by a 15-hour washout period (\>5 half-lives to eliminate any residual effects). This will require three separate visits: a baseline visit, a visit for the first transdermal treatment and a visit for the second transdermal treatment. All visits include fMRI scans. The first transdermal patch will be administered 8-14 hours before the scan. After the washout period, the second transdermal patch will be administered 8-14 hours before the scan. No study team member except for the unblinded team member will know which capsule the participant receives first. Because we are interested in rivastigmine as a probe for a pre-identified computational/physiological abnormality, we will median-split groups post-hoc for the purposes of analysis.
Study: NCT04366518
Drug: Scopolamine
Normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The authors have chosen to use scopolamine to determine the effects of cholinergic antagonism, as treatment with scopolamine demonstrates a dose-related increase in propensity toward conditioned hallucinations and in doses much higher than those proposed here, can cause spontaneous hallucinations. At the proposed dose, scopolamine has an excellent safety profile and has been used routinely for nearly 20 years for treatment of nausea due to surgery or motion sickness in adults and children. Scopolamine is available in the US only as a 1mg / 72 hours transdermal patch, and peak plasma levels are reached within 24 hours. This standard dosage level is very well tolerated in the general population.
Study: NCT06284434
Drug: Liposomal Bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive liposomal bupivacaine mixed with epinephrine (ratio of 1:100,000) for pain management after surgery.
Study: NCT06284434
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive standard bupivacaine mixed with epinephrine (ratio of 1:100,000) for pain management after surgery.
Study: NCT05991973
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: In the time window of 30-180 days after transplantation: oral chidamide 10mg twice a week with a total of 96 courses(4 weeks as a course). If the MRD turns positive during treatment, the dose can be increased to a maximum of 20 mg twice a week, and donor lymphocyte infusion (DLI) is also permitted in the case of MRD positivity.
Study: NCT05765747
Drug: Yunnan Baiyao
Normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yunnan Baiyao group will be given 4 times a day, 2 capsules each time after morning, afternoon and evening meals and before going to bed. One capsule of Baoxianzi will be provided for the first time to be taken at the same time with Yunnan Baiyao Capsule, which will be given continuously for 2 weeks.
Study: NCT06054919
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin D3
Study: NCT06010290
Drug: 18F-SMBT-1
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant receives intravenous injection of 18F-SMBT-1, and undergo PET/CT imaging within the special time. 18F-FP-CIT and 18F-FDG PET/CT are used to assess the change of cerebral dopamine transporters and glucose metabolism for auxiliary diagnosis.
Study: NCT05579665
Drug: Low Molecular Weight Hyaluronic Acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low molecular weight hyaluronic acid which will be injected into the affected knee using ultrasound guidance.
Study: NCT05561062
Drug: Atorvastatin 80mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of its basic lipid-lowering properties
Study: NCT05002530
Drug: Aerosolized 13 cis retinoic acid plus Vitamin D
Normalized name: 13-cis-retinoic acid
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
Study: NCT05002530
Drug: Aerosolized All trans retinoic acid plus Vitamin D
Normalized name: all trans Retinoic acid
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
Study: NCT06108453
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-administration of methotrexate and rifampicin
Study: NCT05946122
Drug: Atorvastatin 40 Mg Oral Tablet
Normalized name: atorvastatin 40 mg oral tablet
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral atorvastatin for renal protection
Study: NCT04676126
Drug: Dorzolamide Hcl 2% Oph Soln
Normalized name: DORZOLAMIDE HCL 2% OPH SOLN
DrugBank: Dorzolamide (DB00869)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical carbonic anhydrase inhibitor
Study: NCT05594849
Drug: Budesonide Orodispersible Tablets (Jorveza)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients that swith to Budesonide Orodispersible Tablets (Jorveza)
Study: NCT04856111
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Same as arm description
Study: NCT04856111
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Same as arm description
Study: NCT04784455
Drug: nomacopan (rVA576)
Normalized name: Nomacopan
DrugBank: Nomacopan (DB14991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within a year of HSCT
Study: NCT05792761
Drug: Peginterferon alfa-2b combined and ETV
Normalized name: peginterferon alfa-2b, combinations
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Child patients are assigned to one of the 3 treatment regimens according to their illness state and treatment desire of their parents/guardians, and the number of patients in each group is expected to limited to 300.~1. NA monotherapy group : received entecavir (ETV) for 96 weeks.~2. Combination therapy group: received peginterferon alfa-2b combined with ETV for 96 weeks.~3. Pulse therapy group :received peginterferon alfa-2b pulse treatment combined with ETV for 144 weeks.
Study: NCT04759742
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to previous clinical experience, 0.5% ropivacaine was given in the subarachnoid cavity, and the initial dose was set at 2.5 mL (12.5mg). Dixon's up-and down method was adopted to adjust or down-adjust the dose of ropivacaine in the next patient according to the experimental results of the previous patient, and the adjusted dose was 0.1 mL (0.5mg).
Study: NCT04999605
Drug: AK112 low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AK112 injection low dose+ olaparib (Lynparza®) PARP inhibitor
Study: NCT04999605
Drug: AK112 high dose
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK112 injection high dose+ olaparib (Lynparza®) PARP inhibitor
Study: NCT00001107
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001107
Drug: AmBisome
Normalized name: AmBisome
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04940182
Drug: XC221
Normalized name: XC221
DrugBank: XC221 (DB16503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive XC221 100 mg 2 times a day during 14 full days
Study: NCT06076824
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention group will recieve 7 mg/kg/day (or a maximum of 500 mg/day) of intravenous Methylprednisolone an hour before TAVR followed by 15 mg / 12h of Prednisone during 5 days after the intervention (starting 24h after the administration of Methylprednisolone).
Study: NCT05834023
Drug: Bupivacaine-Lidocaine
Normalized name: bupivacaine-lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.25% + Lidocaine 1% + dexamethasone 4 mg + epinephrine 5 mcg/ml
Study: NCT05834023
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.5% + dexamethasone 4 mg + epinephrine 5 mcg/ml
Study: NCT04417569
Drug: hCG
Normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: human chorionic gonadotropin
Study: NCT06275425
Drug: Total intravenous anesthesia with Byfavo
Normalized name: Byfavo
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: General anesthesia is maintained with intravenous continuous administration of Byfavo.
Study: NCT06275425
Drug: Inhalation anesthesia with Sevoflurane
Normalized name: sevoflurane Inhalation Solution
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anesthesia is maintained with Sevoflurane.
Study: NCT05780216
Drug: DMT + harmine
DrugBank: Harmine (DB07919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention used in this study is a combination of the two main ingredients of ayahuasca, DMT (N,N-dimethyltryptamine) and harmine in purified form.
Study: NCT04151472
Drug: 90mg Idebenone
DrugBank: Idebenone (DB09081)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Idebenone 30 MG Oral Tablet, three times a day
Study: NCT04151472
Drug: 270mg Idebenone
DrugBank: Idebenone (DB09081)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Idebenone 90 MG Oral Tablet, three times a day
Study: NCT05663164
Drug: Vitamin B
Normalized name: VITAMIN B
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vitamin B1 (100mg) will be diluted in 50 ml 0.9% NACL(normal saline) and administered IV every 6 hours for 3 days
Study: NCT03634839
Drug: Flavoring Agents
Normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavor of e-liquid - sweet or tobacco
Study: NCT03634839
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine level (36 mg/ml)
Study: NCT05840562
Drug: Capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of capsaicin patches 179 mg
Study: NCT05840562
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of duloxetine
Study: NCT06349668
Drug: spinal analgesia with morphine and bupivacaine
Normalized name: bupivacaine and meloxicam
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single shot spinal analgesia with 0.2-0.3 mg morphine and 10-20 mg bupivacaine before surgery
Study: NCT06349668
Drug: lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraoperative intravenous infusion of lidocaine at a rate of 2 mg/kg/t (Ideal Body Weight)
Study: NCT06002646
Drug: Formocresol
Normalized name: Formocresol
DrugBank: Cresol (DB11143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with Formocresol solution
Study: NCT06002646
Drug: Sodium Hypochlorite Solution
Normalized name: sodium hypochlorite solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 3% Sodium Hypochlorite Solution.
Study: NCT05256693
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin (powder) 125mg twice a day
Study: NCT06291675
Drug: gender-affirming hormone therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We are not technically involved in the prescription of gender-affirming hormone therapy. We merely aim at observing effects of GAHT on MRI measured organ lipid content, myocardial mass and function.
Study: NCT06124976
Drug: ST-02
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-02 drug instillation into the upper urinary tract (renal pelvis)
Study: NCT05970978
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IBI112 200mg s.c. at week 0, 4, 8, 20 and 32.
Study: NCT05685394
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10mg P.O. daily
Study: NCT05085561
Drug: REC-994
Normalized name: REC-994
DrugBank: REC-994 (DB15616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: REC-994 200 mg tablets
Study: NCT04919174
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sedation with remimazolam
Study: NCT04919174
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sedation with dexmedetomidine
Study: NCT05562063
Drug: Sotagliflozin
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Daily administration of sotagliflozin (2x200 mg, PO, OD) for 6 months.
Study: NCT05313906
Drug: RC48+AK105+cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RC48 plus AK105 and cisplatin
Study: NCT04102436
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
Study: NCT05234775
Drug: lerodalcibep
Normalized name: Lerodalcibep
DrugBank: Lerodalcibep (DB19071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of each drug given SC as single dose
Study: NCT04102436
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aldesleukin 720,000 IU/kg or 72,000 IU/kg (based on total body weight) IV over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
Study: NCT05275751
Drug: TRPA1-inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid
Study: NCT05275751
Drug: TRPV1-inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid
Study: NCT05275751
Drug: TRPM3-inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid
Study: NCT04469062
Drug: Mirikizumab IV
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04469062
Drug: Mirikizumab SC
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04469062
Drug: Vedolizumab IV
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT05275751
Drug: Chloride-channel inhibitor
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid
Study: NCT05181397
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab.
Study: NCT04017390
Drug: Theraworx Foam
Normalized name: allantoin Topical Foam [Theraworx]
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply Theraworx Foam alone
Study: NCT05585177
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of growth hormone treatment (2 units daily)
Study: NCT05004519
Drug: Dexmedetomidine Injection [Precedex]
Normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine or remifentanil during laparoscopic gastric bypass
Study: NCT05248646
Drug: Sibeprenlimab 400 mg
Normalized name: Sibeprenlimab
DrugBank: Sibeprenlimab (DB18919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibeprenlimab 400 mg s.c. q 4 weeks
Study: NCT04801641
Drug: Nabilone
Normalized name: Nabilone
DrugBank: Nabilone (DB00486)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrated to two 0.5 mg capsules and four placebo capsules taken orally twice daily (Low-Dose) OR Titrated to six 0.5 mg capsules taken orally twice daily (High-Dose)
Study: NCT06301971
Drug: Emraclidine
Normalized name: Emraclidine
DrugBank: Emraclidine (DB18706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution/suspension
Study: NCT05803642
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intramuscular injection, 10 mg/dose, first dose and an optional second or third dose.
Study: NCT05803642
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intramuscular injection, 7.5 mg/dose, first dose and an optional second or third dose.
Study: NCT05247697
Drug: Mirtazapine 7.5 MG Oral Tablet once daily at bedtime
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine 7,5 mg capsule
Study: NCT06180863
Drug: oral azacitidine (CC-486)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral azacitidine is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.